• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears AI Software for Fetal Heart Ultrasound Assessment

News
Article

Reportedly developed on over 90,000 ultrasound exams, the BrightHeart AI software identifies suspicious findings suggestive of congenital heart defects through AI-powered evaluation of fetal heart morphology.

The Food and Drug Administration (FDA) has granted 510(k) clearance for BrightHeart’s artificial intelligence (AI)-enabled software, which may bolster ultrasound detection of congenital heart defects (CHDs) that have been estimated to occur in one of every 100 newborns.

Employing AI algorithms that were developed on over 90,000 ultrasound exams, BrightHeart’s AI software provides automated video stream analysis and detailed assessment of fetal heart morphology, which detects or rules out findings suggestive of CHDs, according to BrightHeart.

FDA Clears AI Software for Fetal Heart Ultrasound Assessment

Offering detailed assessment of fetal heart morphology and automated video stream analysis, the newly FDA-cleared AI software from BrightHeart may enhance ultrasound detection of congenital heart defects. (Image courtesy of BrighHeart.)

The company says the software also offers AI assessment as to the completeness of fetal heart ultrasound exams and facilitates smooth integration into existing ultrasound workflows.

“Fetal heart assessments are among the most technically demanding aspects of prenatal ultrasound,” said Cécile Dupont, the CEO of BrightHeart. “Our AI-powered solution not only assists clinicians in detecting signs of potential abnormalities earlier but also enhances their confidence in confirming normal findings, which is equally critical for the peace of mind of expectant families.”

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.